机构:[1]Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong 518033, People’s Republic of China深圳市康宁医院深圳市中医院深圳医学信息中心[2]Department of Vascular Surgery, Affiliated Hospital of Jiangsu University, 438 Jiefang Road, Zhenjiang, Jiangsu 212001, People’s Republic of China
We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients.
A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality.
EES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) (p = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52-0.99, p = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26-0.73, p = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28-0.98, p = 0.04) and PES (RR = 0.18, 95% CI: 0.07-0.51, p = 0.001).
Among those three types of stents, EES should be the first recommended stent for DM patients.
基金:
Shenzhen Science and Technology Project
(JCYJ20170307155244629) and Guangdong Province Traditional Chinese
Medicine Bureau Project (20182125).
第一作者机构:[1]Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong 518033, People’s Republic of China
通讯作者:
推荐引用方式(GB/T 7714):
Ouyang Hang,Zeng Xuehui,Zhang Chunlei,et al.A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients.[J].JOURNAL OF CARDIOTHORACIC SURGERY.2021,16(1):doi:10.1186/s13019-021-01452-8.
APA:
Ouyang Hang,Zeng Xuehui,Zhang Chunlei,Song Linli,Xu Jiarui...&He Jincai.(2021).A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients..JOURNAL OF CARDIOTHORACIC SURGERY,16,(1)
MLA:
Ouyang Hang,et al."A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients.".JOURNAL OF CARDIOTHORACIC SURGERY 16..1(2021)